Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a strong financial performance for Q3 2021, achieving $9.5 million in total revenue, a 150% increase from $3.8 million in Q3 2020. The company performed 57,000 diagnostics tests in the quarter but reported a net loss of $4.0 million or $(0.26) per share. Cash and equivalents stood at $22.9 million with net working capital of $34.0 million. ProPhase acquired Nebula Genomics for $14.6 million and is optimistic about increasing testing volumes and expanding its diagnostics business.
ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the virtual Q4 Investor Summit Conference on November 16, 2021, at 2:00 PM ET. The conference runs from November 16-17, 2021, and investors can register online. Karkus will also be available for one-on-one meetings during the event.
ProPhase Labs focuses on genomics testing, COVID-19 testing, and consumer healthcare products. The company aims to leverage its CLIA lab services for whole genome sequencing and has a broad range of diagnostic services.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 12, 2021, at 11:00 a.m. ET to discuss Q3 results ending September 30, 2021. CEO Ted Karkus will lead the call, followed by a Q&A session. Registration is necessary to access the call, with a toll-free dial-in option available. ProPhase is a diversified biotech firm focused on genomic testing and CLIA lab services, including COVID-19 testing. The company aims to build a genomic database and expand its services internationally.
ProPhase Labs (NASDAQ: PRPH) announced a decline in expected Q3 2021 COVID-19 testing revenues due to lower summer testing rates. However, the company anticipates a rebound in Q4 2021, aiming to match record Q1 revenues driven by government mandates and an increasing customer base. CEO Ted Karkus noted heightened testing levels in October and ongoing organic growth. The integration of Nebula Genomics into ProPhase's operations is advancing as planned, promising faster genomic testing and lower prices, which may significantly boost sales in 2022.
GARDEN CITY, NY, Oct. 6, 2021 -- ProPhase Labs, Inc. (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present virtually at the 14th Annual LD Micro Main Event Conference. This presentation is scheduled for October 14, 2021, at 9:30 AM ET. ProPhase Labs is a diversified biotech and genomics company, leveraging its CLIA lab services for whole genome sequencing and COVID-19 testing. The company aims to expand its testing capabilities globally and enhance its genomics database for research purposes.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced that CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, virtually held from September 29-30, 2021. Karkus's presentation is scheduled for September 29 at 2:20 PM ET. Investors can register for the conference online. ProPhase Labs is a diversified biotech and genomics company focused on whole genome sequencing and CLIA lab services, including COVID-19 testing. The firm also aims to expand its testing services internationally and enhance genomic data research.
ProPhase Labs (NASDAQ: PRPH) has authorized a stock repurchase program of up to $6 million to enhance shareholder value. The buyback will occur over the next six months via various market transactions, with decisions based on market conditions and company needs. CEO Ted Karkus expressed confidence in the company's momentum, anticipating strong revenue growth for ProPhase Diagnostics due to ongoing COVID-19 testing demand. Additionally, the integration of Nebula Genomics is expected to boost personalized medicine initiatives, aiming for reduced costs and faster results.
ProPhase Labs, a diversified biotech and genomics company, announced that its Chairman and CEO, Ted Karkus, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. Karkus's corporate presentation will be available starting September 13 at 7:00 AM ET. Investors can register for the event on the conference website. ProPhase Labs focuses on genomics testing technologies and offers various diagnostic services, including COVID-19 testing, with results provided in under 24 hours.
ProPhase Labs (Nasdaq: PRPH) has announced that Chairman and CEO Ted Karkus will present at two upcoming investor conferences. He is set to deliver a corporate presentation at the Q3 Investor Summit on August 17, 2021, at 11:00 am ET. Additionally, he will present at the SNN Network Summer Virtual Event on August 18, 2021, at 2:00 pm ET. Management will be available for one-on-one meetings throughout both events. ProPhase Labs focuses on genomics testing and provides COVID-19 testing services.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a significant financial turnaround for Q2 2021. Total revenue surged to $9.1 million, up 153% from $3.6 million in Q2 2020. However, the company reported a net loss of $1.4 million, equating to $(0.09) per share, reversing from a net income of $70,000 in the prior year. The acquisition of Nebula Genomics is expected to expand its service offerings, and the firm maintained a strong cash position of $35.8 million post-dividend.